BMG, Julphar to launch women's health portfolio
Milan/Ras Al Khaimah, July 29, 2013
BMG Pharma and Julphar-Gulf Pharmaceutical Industries have entered into a partnership agreement to launch an innovative women’s health portfolio.
Under the terms of the licence and supply agreement, Julphar will exclusively register and market BMG's proprietary technology products in women's health under the BMG Ginoxil brand in the Middle East and Africa.
The agreement will enable Julphar to introduce this innovative portfolio in a fast growing and largely self-payment driven market.
These products have been developed to address major unmet needs of patients and physicians in the evolving Middle East and Africa (MEA) market. Julphar expects to launch this family of products directly from early 2014 onwards.
“We believe this partnership with Julphar, a leading company in the MEA countries with whom we share vision and values, is the key to growing sales of BMG's women's health products," said Marco Mastrodonato, president and CEO of BMG Pharma, an Italian specialty pharmaceutical company.
“This long-term partnership is a major milestone for BMG as it opens us the door to one of the most exciting healthcare markets in the world," he said.
"Julphar recognises and acknowledges market demands within our region for increasing accessibility of specialised women's products. It is an honour to partner with BMG on this mission to fulfill a clearly identified market need and provide high-quality products," said a statement from Julphar.
"Women's health is a sizable market segment which has been somewhat under-served in our region. We look forward to continuing to expand our portfolio and better serving patients' needs,” the statement added. - TradeArabia News Service